Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus MEASURIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus MEASURIN.
DUEXIS vs MEASURIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Measurin is an aspirin preparation that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin and thromboxane synthesis. This results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
None Documented
None Documented
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Plasma elimination half-life is 2-3 hours at low doses (antiplatelet) and increases to 15-30 hours at anti-inflammatory doses due to saturation of hepatic metabolism; clinical context: higher doses require longer dosing intervals to avoid accumulation.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid) accounts for >90% of elimination; minor biliary/fecal excretion (<5%) occurs.
Category C
Category C
NSAID/H2 Antagonist Combination
NSAID